Amgen pleads guilty to misbranding charges, will pay $762 mln
NEW YORK Dec 18 (Reuters) - Amgen Inc pleaded guilty in a federal court in New York on Tuesday to misbranding its Aranesp anemia drug and agreed to pay $762 million in a civil settlement and criminal fines.
The company, the largest in the global biotechnology sector, had already set aside funds it expected to have to pay as a result of federal and state investigations as well as nearly a dozen civil whistleblower lawsuits.
Federal prosecutors said in court that the company was paying a $612 million civil settlement, a $14 million forfeiture, and a $136 million criminal fine.
Amgen entered the guilty plea, but no sentence has been issued.
Aranesp is one of Amgen's largest drugs and had sales of $2.3 billion in 2011.
A spokeswoman for the company, based in Thousand Oaks, California, declined to give an immediate comment.
(Writing by Caroline Humer; Editing by Lisa Von Ahn)
- Obama and Castro shake hands, Zuma humiliated at Mandela memorial |
- Google bus blocked in San Francisco gentrification protest
- Reporter can keep sources secret in Colorado theater shooting: court
- Thai PM urges protesters to take part in election |
- Regulators seek to curb Wall St. trades with Volcker rule